Adjuvant Radioimmunotherapy for Glioma Patients
Author Information
Author(s): Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G
Primary Institution: European Institute of Oncology
Hypothesis
Can pretargeted adjuvant radioimmunotherapy improve time to relapse and overall survival in high grade glioma patients?
Conclusion
The study suggests that three-step radioimmunotherapy may significantly improve survival and disease-free intervals in high grade glioma patients.
Supporting Evidence
- In treated glioblastoma patients, median survival was 33.5 months compared to 8 months in controls.
- Median disease-free interval for treated glioblastoma patients was 28 months.
- Only two of the 11 treated grade III glioma patients died, indicating potential effectiveness.
Takeaway
This study tested a new treatment for brain cancer that helps patients live longer and stay healthier after surgery.
Methodology
The study enrolled 37 high grade glioma patients and compared outcomes between those receiving adjuvant radioimmunotherapy and a control group.
Potential Biases
Potential selection bias due to non-randomized design.
Limitations
The study was non-randomized and had a small sample size.
Participant Demographics
37 patients, 16 females and 21 males, aged 19-83 years.
Statistical Information
P-Value
0.014
Confidence Interval
95% CI=(20, NA)
Statistical Significance
p=0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website